Format

Send to

Choose Destination
Stroke. 2011 Nov;42(11):3291-3. doi: 10.1161/STROKEAHA.111.625046. Epub 2011 Sep 1.

Telestroke-guided intravenous tissue-type plasminogen activator treatment achieves a similar clinical outcome as thrombolysis at a comprehensive stroke center.

Author information

1
University of Pittsburgh Medical Center Stroke Institute, Pittsburgh, PA, USA.

Abstract

BACKGROUND AND PURPOSE:

Telestroke networks offer an opportunity to increase tissue-type plasminogen activator use in community hospitals.

METHODS:

We compared 83 patients treated with intravenous tissue-type plasminogen activator by telestroke to 59 patients treated after in-person evaluation by the same neurologists at a tertiary care stroke center. Onset and door-to-treatment times and functional outcome at 90 days were obtained prospectively. Favorable outcome was defined as modified Rankin Scale score ≤2.

RESULTS:

Favorable outcome rates were comparable between the groups (42.1% versus 37.5%, P=0.7). There was no significant difference in the rate of symptomatic hemorrhage.

CONCLUSIONS:

Telestroke is a viable alternative to in-person evaluation when stroke expertise is not readily available.

PMID:
21885843
DOI:
10.1161/STROKEAHA.111.625046
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center